EP Patent

EP3500575B8 — Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Assigned to BeOne Medicines I GmbH · Expires 2026-02-25 · 0y expired

What this patent protects

Patent listed against Brukinsa.

Drugs covered by this patent

Patent Metadata

Patent number
EP3500575B8
Jurisdiction
EP
Classification
—
Expires
2026-02-25
Drug substance claim
No
Drug product claim
No
Assignee
BeOne Medicines I GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.